Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:PMN NASDAQ:SCLX NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.25+19.7%$1.43$0.86▼$3.36$136.29M0.2335,670 shs1.45 million shsPMNPromis Neurosciences$0.51-10.5%$0.52$0.38▼$1.59$27.44M-0.172.71 million shs1.42 million shsSCLXScilex$17.68+0.6%$20.45$3.60▼$39.90$122.98M1.36151,162 shs190,557 shsSPROSpero Therapeutics$2.36+3.5%$2.02$0.51▼$3.22$132.82M1.471.64 million shs581,240 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+7.43%+33.33%+44.62%-20.34%PMNPromis Neurosciences+5.29%+24.91%+30.34%+41.52%-44.70%SCLXScilex-3.57%-14.99%-20.70%+170.88%-40.16%SPROSpero Therapeutics+5.56%+16.33%+14.00%-19.72%+83.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.25+19.7%$1.43$0.86▼$3.36$136.29M0.2335,670 shs1.45 million shsPMNPromis Neurosciences$0.51-10.5%$0.52$0.38▼$1.59$27.44M-0.172.71 million shs1.42 million shsSCLXScilex$17.68+0.6%$20.45$3.60▼$39.90$122.98M1.36151,162 shs190,557 shsSPROSpero Therapeutics$2.36+3.5%$2.02$0.51▼$3.22$132.82M1.471.64 million shs581,240 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+7.43%+33.33%+44.62%-20.34%PMNPromis Neurosciences+5.29%+24.91%+30.34%+41.52%-44.70%SCLXScilex-3.57%-14.99%-20.70%+170.88%-40.16%SPROSpero Therapeutics+5.56%+16.33%+14.00%-19.72%+83.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 2.60Moderate Buy$7.00211.11% UpsidePMNPromis Neurosciences 2.50Moderate Buy$4.33749.67% UpsideSCLXScilex 2.20Hold$455.002,473.53% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.00111.86% UpsideCurrent Analyst Ratings BreakdownLatest PMN, SPRO, ABOS, and SCLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025PMNPromis NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SCLXScilexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SPROSpero TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025SPROSpero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/27/2025ABOSAcumen PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PMNPromis NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SCLXScilexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SPROSpero TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/25/2025ABOSAcumen PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.007/21/2025PMNPromis NeurosciencesLeede FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy7/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$3.03 per shareN/APMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ASCLXScilex$44.24M2.78N/AN/A($27.68) per share-0.64SPROSpero Therapeutics$47.98M2.77N/AN/A$0.85 per share2.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$102.33M-$2.28N/AN/AN/AN/A-81.39%-61.96%11/11/2025 (Estimated)PMNPromis Neurosciences$2.78M-$0.21N/AN/AN/AN/A-266.69%-131.59%11/13/2025 (Estimated)SCLXScilex-$72.81M-$29.02N/AN/AN/A-179.12%N/A-109.95%11/12/2025 (Estimated)SPROSpero Therapeutics-$68.57M-$0.98N/AN/AN/A-110.35%-120.27%-55.61%11/13/2025 (Estimated)Latest PMN, SPRO, ABOS, and SCLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PMNPromis Neurosciences-$0.22-$0.29-$0.07-$0.29N/AN/A8/13/2025Q2 2025SCLXScilex-$4.55-$7.42-$2.87-$7.42$26.25 million$9.90 million8/12/2025Q2 2025ABOSAcumen Pharmaceuticals-$0.54-$0.68-$0.14-$0.68N/AN/A8/12/2025Q2 2025SPROSpero Therapeutics-$0.38-$0.03+$0.35-$0.03$11.00 million$14.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.265.975.97PMNPromis NeurosciencesN/A0.970.97SCLXScilexN/A0.110.10SPROSpero TherapeuticsN/A3.973.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%PMNPromis Neurosciences50.13%SCLXScilex69.67%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%PMNPromis Neurosciences6.11%SCLXScilex7.94%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million54.94 millionOptionablePMNPromis Neurosciences553.81 million50.52 millionNot OptionableSCLXScilex806.96 million6.40 millionNo DataSPROSpero Therapeutics15056.28 million53.18 millionOptionablePMN, SPRO, ABOS, and SCLX HeadlinesRecent News About These CompaniesSpero Therapeutics' (SPRO) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 9 at 2:33 AM | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Rating Increased to Strong-Buy at Zacks ResearchOctober 8 at 7:33 AM | marketbeat.comAnalysts Set Spero Therapeutics, Inc. (NASDAQ:SPRO) PT at $5.00October 6 at 3:47 AM | americanbankingnews.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Receives Consensus Rating of "Hold" from BrokeragesOctober 3, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest UpdateSeptember 16, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Drop in Short InterestSeptember 9, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Director Sells $12,946.84 in StockSeptember 4, 2025 | insidertrades.comDown 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a TurnaroundAugust 19, 2025 | zacks.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 13, 2025 | finanznachrichten.deSpero Therapeutics Reports Q2 2025 Results and Trial SuccessAugust 13, 2025 | msn.comSpero Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comSpero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comSpero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 12, 2025 | globenewswire.comSpero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025August 5, 2025 | globenewswire.comWhile institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 28, 2025 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSpero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11, 2025 | seekingalpha.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | msn.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | insidermonkey.comGSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMCMay 30, 2025 | pharmabiz.comPNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025ISRG, TEAM, SFM Trade Well Below Highs With 30%+ UpsideBy Leo Miller | September 23, 2025Sprouts, Darden Offer High-Upside Setups for Risk-TakersBy Sam Quirke | September 26, 2025PMN, SPRO, ABOS, and SCLX Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$2.25 +0.37 (+19.68%) Closing price 04:00 PM EasternExtended Trading$2.26 +0.00 (+0.22%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Promis Neurosciences NASDAQ:PMN$0.51 -0.06 (-10.46%) Closing price 04:00 PM EasternExtended Trading$0.50 -0.01 (-0.98%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Scilex NASDAQ:SCLX$17.68 +0.10 (+0.57%) Closing price 04:00 PM EasternExtended Trading$17.68 +0.00 (+0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.Spero Therapeutics NASDAQ:SPRO$2.36 +0.08 (+3.51%) Closing price 04:00 PM EasternExtended Trading$2.35 -0.01 (-0.59%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
